中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere Announces Appointment of Mr. Zhou Gaobo as Chief Investment Officer

On January 17, 2022, Simcere Pharmaceutical Group (2096.HK) announced the appointment of Mr. Zhou Gaobo as Chief Investment Officer. He will be in cha...

2022-01-18
Trilaciclib Received Priority Review from NMPA! Patient Enrolment Achieved for Three Indications in Phase III Study in China

On January 7 2022，Simcere Pharmaceutical Group (2096.HK) announced that Trilaciclib for injection, an innovative anti-tumor and myeloprotection therap...

2022-01-10
Simcere Announced CTA Approval for SCR6852, an investigational SERD molecule that can Cross Blood-brain-barrier for breast cancer treatment

December 28, 2021, Simcere Pharmaceutical Group announced that SCR-6852 capsule, an orally selective estrogen receptor degrader (SERD) independently d...

2022-01-07
FDA Fast Track Designation granted for Varoglutamstat in Early Alzheimer’s disease

Simcere Pharmaceutical Group Limited (HKEX: 2096) announced today that varoglutamstat (PQ912，SIM0408), an investigational oral small molecule medici...

2021-12-23
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.